Aragon Pharmaceuticals is a technology company.
Aragon Pharmaceuticals has raised $80.0M across 3 funding rounds.
Key people at Aragon Pharmaceuticals.
Aragon Pharmaceuticals has raised $80.0M in total across 3 funding rounds.
Key people at Aragon Pharmaceuticals.
Aragon Pharmaceuticals was a biotechnology company specializing in small-molecule drug discovery for hormonally-driven cancers, particularly those resistant to first-generation antihormonal therapies, such as castration-resistant prostate cancer and breast cancer[1][2][3]. Its lead product, ARN-509 (later developed as apalutamide), targeted androgen receptor signaling inhibition and advanced to Phase II/III trials, addressing unmet needs in advanced prostate cancer treatment where existing options were ineffective or toxic[1][4][5][6]. The company served oncology patients and physicians, solving the problem of hormone therapy resistance by developing second-generation agents that block and degrade hormone receptors, with potential expansion to early-stage prostate, breast, endometrial, and ovarian cancers[1][5]. Aragon was acquired by Johnson & Johnson in August 2013 for $650 million upfront plus up to $350 million in milestones, totaling potentially $1 billion, after spinning off its estrogen receptor program to Seragon Pharmaceuticals[1][4][5].
Aragon Pharmaceuticals emerged from pioneering research by Charles Sawyers on molecular mechanisms of drug resistance in hormone-driven cancers, building on his prior work that contributed to imatinib (Gleevec) for leukemia[3][5]. Founded around 2007-2008 (exact year not specified in sources), it was co-founded by key figures including CEO Richard A. Heyman, PhD, who previously served as Chief Scientific Officer at X-Ceptor Therapeutics (acquired by Exelixis in 2004) and held research leadership at Ligand Pharmaceuticals, where he advanced FDA-approved cancer retinoids[3]. Other notable team members included executives with deep experience at Amgen, Pfizer, IDEC (Biogen Idec), and Exelixis, bringing expertise in drug development, commercialization, and business deals like Rituxan and out-licensing to Genentech[3]. Early traction came from advancing ARN-509 into Phase I/II trials for progressive castration-resistant prostate cancer, culminating in the high-value J&J acquisition that validated its science[1][4][5].
Aragon rode the wave of precision oncology in the late 2000s-early 2010s, focusing on endocrine-driven cancers amid rising demand for therapies targeting resistance mechanisms in prostate and breast cancers[1][5]. Timing was ideal as first-line antihormonals like abiraterone (Zytiga, from J&J) gained traction, but resistance limited options—Aragon's second-generation inhibitors filled this gap, influencing J&J's oncology dominance[4]. Market forces like aging populations, increasing cancer incidence, and biotech M&A booms favored its model, with the $1 billion deal underscoring investor appetite for hormone receptor innovations[5]. Post-acquisition, Aragon's tech bolstered Janssen's pipeline, contributing to apalutamide's approval and shaping competitive dynamics against therapies like enzalutamide, while its Seragon spin-off (later acquired by Gilead) expanded estrogen receptor degrader ecosystems[5][6].
Aragon's legacy endures through apalutamide, a cornerstone in prostate cancer treatment integrated into J&J's portfolio, with ongoing Phase 3 expansions and combinations addressing metastatic disease[6]. Next steps involve Janssen leveraging it in broader oncology combos amid trends like ADCs, PSMA-targeted therapies, and resistance-overcoming bispecifics in a $10B+ prostate market[1][6]. As biotech consolidates, Aragon exemplifies how targeted biotech exits amplify impact, evolving from startup innovator to global standard-setter in hormonally-driven cancers—reinforcing that niche resistance-breakers drive enduring ecosystem value.
Aragon Pharmaceuticals has raised $80.0M in total across 3 funding rounds.
Aragon Pharmaceuticals's investors include Aisling Capital, General Atlantic, OrbiMed, The Column Group.
Aragon Pharmaceuticals has raised $80.0M across 3 funding rounds. Most recently, it raised $50.0M Series D in October 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2012 | $50.0M Series D | Aisling Capital, General Atlantic, OrbiMed, The Column Group | |
| Apr 1, 2010 | $22.0M Series B | Aisling Capital, General Atlantic, OrbiMed, The Column Group | |
| May 1, 2009 | $8.0M Series A | OrbiMed, The Column Group |
